Is Piramal Pharma (PPLPHARMA) overvalued or fairly valued?

MarketChacha shows Piramal Pharma's valuation in context — a forward P/E of about 42.1, a price-to-book of about 2.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Piramal Pharma's revenue?

Piramal Pharma reported revenue of ₹4,782 Cr for FY2026, with net profit of ₹700 Cr, per official filings.

What is the share price of Piramal Pharma (PPLPHARMA)?

Piramal Pharma last traded at ₹177.10 (-1.0% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Piramal Pharma

PPLPHARMA · NSE · Pharma · India

₹177.10-1.0%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerPPLPHARMA

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees7,120

HeadquartersMumbai, India

Market cap₹23,498 Cr

P/B2.7

Volume88.12L

Websitewww.piramalpharma.com

Filings tracked0

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. The company was incorporated in 2020 and is based in Mumbai, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters54.5%
Institutions21.9%
Public & other23.6%

63 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

What's expected next

Next quarter

Rev ₹2,313 Cr

Est. earnings growth +100.0%

Next fiscal year

Rev ₹11,549 Cr · EPS 4.21

Est. earnings growth +206.6%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹132.3052-wk range₹210.50

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Quarterly · last 2

Market cap

₹23,498 Cr

Day change

-1.0%

Fwd P/E

42.1

P/B

2.7

Div yield

0.08%

Beta

0.39

Revenue (FY2026)

₹4,782 Cr

Net margin

14.6%

EPS (FY2026)

5.28

Net profit (FY2026)

₹700 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about PPLPHARMA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹4,782 Cr	₹700 Cr	5.28	14.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	₹1,489 Cr	₹262 Cr	1.97	17.6%
2025Q4	₹1,196 Cr	₹129 Cr	0.97	10.8%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.